### Oral Poster Presentation Schedule

**Friday, September 5, 2014**  
Gracia 1/Level 3  
7:00 am – 8:00 am

<table>
<thead>
<tr>
<th>Time</th>
<th>Number</th>
<th>Title and Authors</th>
</tr>
</thead>
</table>
| 7:00 am   | 17     | **Peripheral Edema and Weight Gain in Adult Patients with Painful Diabetic Peripheral Neuropathy (DPN) Receiving Gabapentin Enacarbil (GEn) or Pregabalin Enrolled in a Randomized Phase 2 Trial**  
Anne Calkins¹, Joseph Shurman¹,², Mark Jaros¹,³, Richard Kim¹,⁴, Gwendoline Shang¹,⁴, ¹New York Spine and Wellness Center, North Syracuse, NY, USA, ²Scripps Memorial Hospital, La Jolla, CA, USA, ³Summit Analytical, LLC, Denver, CO, USA, ⁴XenoPort, Inc., Santa Clara, CA, USA |
| 7:12 am   | 113    | **Balancing Pain Relief and Opioid-Induced Gastrointestinal Side Effects: Insights from a Structured Review of Social Media Platforms**  
Cynthia B. Whitman¹, Corey Arnold², Haridarshan Patel³, Justin L. Scope⁴, Mark Reid¹,⁵, Brennan M.R. Spiegel¹,⁵, ¹Cedars-Sinai Center for Outcomes Research and Education, Los Angeles, CA, USA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, ³Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals, Inc., Deerfield, IL, USA, ⁴US Medical Affairs, Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, ⁵VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA |
| 7:24 am   | 139    | **Pregabalin in fibromyalgia patients taking antidepressant medication for comorbid depression: A comprehensive overview of a randomized, two-way crossover, double-blind, placebo-controlled study**  
Richard Vissing¹, Jaren Landen², Pritha Bhadra Brown³, Joseph Scavone², Andrew Clair⁵, Lynne Pauer⁵, ¹Pfizer Inc, Louisville, KY, USA, ²Pfizer Inc, Groton, CT, USA, ³Pfizer Inc, New York, NY, USA |
| 7:36 am   | 140    | **Epidemiology of Conditions Associated with Pain and the Use of Analgesic and Non-Analgesic Treatments in Pediatrics**  
Laura Wallace¹, Stacy Baldridge¹, Rayna Matsuno¹, ¹Purdue Pharma LP, Stamford, CT, USA |
| 7:48 am   | 155    | **SoluMatrix® Diclofenac Demonstrates Sustained Opioid-sparing Effects in a Phase 3 Study of Patients With Acute Pain Following Elective Surgery**  
Charles Argoff¹, Srinivas Nalamachu², Lynn Webster³, Jeff Gudin⁴, Clarence Young⁵, ¹Albany Medical College, Albany, NY, USA, ²Kansas City University of Medicine and Biosciences, Kansas City, MO, USA, ³CRI-Lifetree, Mount Laurel, NJ, USA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, USA, ⁵Iroko Pharmaceuticals, LLC, Philadelphia, PA, USA |
| 8:00 am   | 145    | **Intranasal Human Abuse Potential of a Novel Abuse-deterrent Extended-release Formulation of Morphine**  
Lynn Webster¹, Carmela Pantaleon², Monish S Shah³, Ray DiFalco³, Matthew Iverson², Michael D Smith¹, Eric R Kinzler², Stefan Aigner², ¹PRA Health Sciences, Salt Lake City, Utah, USA, ²Inspiron Delivery Technologies LLC, Valley Cottage, New York, USA, ³Cerovene, Valley Cottage, New York, USA |